Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{161881,
        author = {Shrenik M. Mane and Jivan S. Kharat and Shubhangi J. Shid},
        title = {Review Paper of Dostarlimab},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {10},
        number = {6},
        pages = {487-492},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=161881},
        abstract = {Dostarlimab is a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor from interacting with its ligands, PD-L1 and PD-L2. This interaction between PD-1 and its ligands can suppress the immune system's ability to attack cancer cells. By blocking this interaction, dostarlimab can help to unleash the immune system to fight cancer.Dostarlimab is also generally well-tolerated with a relatively mild side effect profile. The most common side effects are fatigue, nausea, diarrhea, and rash. These side effects are typically mild and manageable, and they often go away on their own or with supportive care.Dostarlimab is a relatively new drug, and it is still too early to say what its long-term safety and efficacy are. However, the results from clinical trials so far have been very promising. We will discuss the mechanism of action, trial phase performance and side effects of Dostarlimab drug.  },
        keywords = {},
        month = {},
        }